Proceedings from the 1st Insights in Hematology Symposium, Cluj-Napoca, Romania March 11-12, 2016

Abstract

In the March 2016 issue of the Lancet Haematology, the editorial office published a paper stating the roadmap for European research in hematology, based on the European Hematology Association (EHA) consensus document that outlines the directions in hematology for the following years across the continent. The meeting entitled “Insights in hematology” is organized a support for the initiative of a roadmap for European hematologists regarding research, may it be basic research or clinical research, but this consensus should not be focused mainly on European institutions, but rather form the backbone of global research between Europe and the United States, Japan or any other country. This will allow Europeans to learn as well as to share their experience with the rest of the scientific and medical community. And the Cluj-Napoca meeting should be followed by other such meetings all across the EU.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. THE LANCET HAEMATOLOGY. A roadmap for European research. Lancet Haematol. 2016; 3(3):e99.

  • 2. TOMULEASA C., FUJI S., CUCUIANU A., KAPP M., PILECZKI V., PETRUSHEV B., et al. MicroRNAs as biomarkers for graft-versus-host disease following allogeneic stem cell transplantation. Ann Hematol. 2015; 94(7):1081-92.

  • 3. BRAICU C., TOMULEASA C., MONROIG P., CUCUIANU A., BERINDAN-NEAGOE I., CALIN G.A. Exosomes as divine messengers: are they the Hermes of modern molecular oncology? Cell Death Differ. 2015; 22(1):34-45.

  • 4. BERINDAN-NEAGOE I., MONROIG P DEL C., PASCULLI B., CALIN G.A. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin. 2014; 64(5):311-36.

  • 5. TOMULEASA C., AKIN-ABAYOMI E., DIMA D., TEFAS C., IRIMIE A., PETRUSHEV B., et al. Do lymphomas have an autoimmune background and how can we increase the sensitivity of the diagnosis of primary pancreatic lymphoma with relatively small samples? J Gastrointestin Liver Dis. 2015; 24(3):391-2.

  • 6. GREWAL R., CUCUIANU A., SWANEPOEL C., DIMA D., PETRUSHEV B., POP B., et al. The role of microRNAs in the pathogenesis of HIV-related lymphomas. Crit Rev Clin Lab Sci. 2015; 52(5):232-41.

  • 7. BRAMMER J.E., KHOURI I., GABALLA S., ANDERLINI P., TOMULEASA C., AHMED S., et al. Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning. Biol Blood Marrow Transplant. 2016; 22(3):493-8.

  • 8. TANASE A., TOMULEASA C., MARCULESCU A., BARDAS A., COLITA A., ORBAN C., et al. Haploidentical Donors: Can Faster Transplantation Be Life-Saving for Patients with Advanced Disease? Acta Haematol. 2016; 135(4):211-216.

  • 9. TANASE A., TOMULEASA C., MARCULESCU A., BARDAS A., COLITA A., CIUREA S.O. First successful haploidentical stem cell transplantation in Romania. Rom J Intern Med 2016, in press.

  • 10. PETRUSHEV B., BOCA S., SIMON T., BERCE C., FRINC I., DIMA D., et al. Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy. Int J Nanomedicine. 2016; 11:641-60.

  • 11. SUARASAN S., SIMON T., BOCA S., TOMULEASA C., ASTILEAN S. Gelatin coated gold nanoparticles as carriers of FLT3 inhibitors for acute myeloid leukemia treatment. Chem Biol Drug Des. 2016; doi:

    • Crossref
    • Export Citation
  • 12. SIMON T., TOMULEASA C., BOJAN A., BERINDAN-NEAGOE I., BOCA S., ASTILEAN S. Design of FLT3 Inhibitor - Gold Nanoparticle Conjugates as Potential Therapeutic Agents for the Treatment of Acute Myeloid Leukemia. Nanoscale Res Lett. 2015; 10(1):466.

  • 13. CIUREA S.O., ZHANG M.J., BACIGALUPO A.A., BASHEY A., APPELBAUM F.R., ALJITAWI O.S., et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015; 126(8):1033-40.

  • 14. TOMULEASA C., DIMA D., FRINC I., PATIU M., PETRUSHEV B., CUCUIANU A., et al. BCR-ABL1 T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice. Leuk Lymphoma. 2015; 56(2):546-7.

  • 15. ALONSO S., SU M., JONES J.W., GANGULY S., KANE M.A., JONES R.J., et al. Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes. Oncotarget. 2015; 6(17):14905-12.

  • 16. SU M., ALONSO S., JONES J.W., YU J., KANE M.A., JONES R.J., et al. All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment. PLoS One. 2015; 10(6):e0127790.

  • 17. MCCORMACK E., HAALAND I., VENAS G., FORTHUN R.B., HUSEBY S., GAUSDAL G., et al. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 2012; 26(5):910-7.

  • 18. MCCORMACK E., MUJIC M., OSDAL T., BRUSERUD Ø., GJERTSEN B.T. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood. 2013; 121(7):e34-42.

  • 19. TANASE A., SCHMITZ N., STEIN H., BOUMENDIL A., FINEL H., CASTAGNA L., et al. Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party. Leukemia. 2015; 29(3):686-8.

  • 20. TRIFA A.P., POPP R.A., CUCUIANU A., BANESCU C., TEVET M., MARTIN B., et al. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients. Br J Haematol. 2015; 168(1):151-3.

  • 21. TOMULEASA C., BRAICU C., IRIMIE A., CRACIUN L., BERINDAN-NEAGOE I. Nanopharmacology in translational hematology and oncology. Int J Nanomedicine. 2014; 9:3465-79.

OPEN ACCESS

Journal + Issues

Search